Niemann-Pick type C1 disease (NPC1) is an autosomal recessive lysosomal storage disorder characterized by neonatal jaundice, hepatosplenomegaly, and progressive neurodegeneration. The present study provides the lipid profiles, mutations, and corresponding associations with the biochemical phenotype obtained from NPC1 patients that participated in the National NPC1 Disease Database. Lipid profiles were obtained from 34 patients (39%) in the survey, and demonstrated significantly reduced plasma low density lipoprotein cholesterol (LDL-C) and increased plasma triglycerides in the majority of patients. Reduced plasma high density lipoprotein cholesterol (HDL-C) was the most consistent lipoprotein abnormality found in male and female NPC1 patients across age groups, and occurred independent of changes in plasma triglycerides. A subset of 19 patients for whom the biochemical severity of known NPC1 mutations could be correlated with their lipid profile showed a strong inverse correlation between plasma HDL-C and severity of the biochemical phenotype. Gene mutations were available for 52 patients (59%) in the survey, including 52 different mutations and 5 novel mutations (Y628C, P887L, I923V, A1151T, and 3741_3744delACTC).
INTRODUCTION
Niemann-Pick type C1 disease (NPC1) is an autosomal recessive lipid storage disorder characterized by clinical manifestations involving primarily the liver and brain (1) . The onset of signs or symptoms can occur at any age and have a variable phenotype. The classic clinical phenotype is also variable and includes mid-to-late childhood onset of gait disturbance followed by progressive neurodegeneration with vertical gaze palsy, seizures, and dementia, resulting in death during the second or third decade (2) (3) (4) . The clinical phenotype of NPC1 disease has been categorized according to the age of onset of symptoms (5, 6) , including an early-onset, rapidly progressive form associated with hepatic dysfunction and psychomotor delay during infancy, the classic form, and a lateonset type characterized by a slowly progressive intellectual impairment in adolescence or adulthood.
The gene responsible for NPC1 disease, NPC1, was localized to chromosome 18 using linkage analysis and subsequently identified using positional mapping and molecular cloning techniques (7, 8) . The encoded product, the Niemann-Pick C1 (NPC1) protein, contains several specialized regions (9) (10) (11) , including a sterol-sensing domain also present in other key proteins regulating cholesterol metabolism, including 3-hydroxy-3-methyl-glutaryl-CoA reductase and SREBP cleavage-activating protein (SCAP) (12, 13) . Recent studies indicate cholesterol binds to luminal loop-1 of NPC1 (14) , and that a separate N-terminal helical subdomain of NPC1 is required for cholesterol transfer between NPC2 and the cholesterol-binding domain of NPC1 (15) .
At the cellular level, decreased NPC1 protein function results in an accumulation of both cholesterol and glycosphingolipids within late endosomes and lysosomes (16) (17) (18) (19) . As a result, it is believed that the NPC1 protein has a central role in regulating the transport of these lipids out of late endosomes/lysosomes to other cellular compartments, including the Golgi apparatus, plasma membrane, and endoplasmic reticulum (20) (21) (22) (23) .
Consistent with this proposed function, studies performed in human and mouse fibroblasts have demonstrated that the NPC1 protein is primarily localized to a novel late endosome-like compartment capable of transiently interacting with LDL-derived cholesterol-enriched late endosomes/lysosomes (24, 25) .
Since identification of the NPC1 gene, a number of studies have characterized various mutations and attempted to associate these mutations with a biochemical and clinical phenotype (26) (27) (28) (29) . To date, more than 243 different loss-of-function mutations of NPC1 have been reported [http://npc.fzk.de/index.php?section=about and (30) ], in addition to 60 different non-disease causing polymorphisms (30) (31) (32) (33) . Although the ability to establish meaningful genotype and clinical phenotype associations has been difficult, primarily due to the fact that most NPC1 patients are compound heterozygous for different mutations, some associations have been established for NPC1 patients with homozygous mutations. In particular, the relatively common I1061T mutation, present in approximately 20% of all known mutations for NPC1 and prominent among individuals of Western European descent, predisposes patients to the classic NPC1 clinical phenotype (33, 34) .
Defects in cholesterol trafficking out of lysosomes might be expected to produce changes in plasma lipoprotein levels. We previously reported low plasma high density lipoprotein cholesterol (HDL-C) levels in 17 of 21 NPC disease patients studied, and provided evidence using human NPC1 -/-fibroblasts that this is due to defective upregulation of the key transporter mediating new HDL particle formation, ATP-binding cassette transporter A1 (ABCA1), as a consequence of impaired release of cholesterol from lysosomes (35) . We also found a tendency towards reduced plasma low density lipoprotein cholesterol (LDL-C) and increased plasma triglycerides in these patients (35) . In the current study we sought to determine whether these abnormalities are a consistent feature of NPC1 disease, and whether the reduction in HDL-C might be a reflection of the biochemical severity of the disease.
Recently, two independent reports including ours have been published providing an in depth analysis of the natural history, clinical features, and disabilities associated with NPC1 disease (36, 37) . These reports confirm the heterogeneous nature of NPC1 disease, and have identified particular symptoms including cataplexy and epilepsy being more common than previously reported. The present analysis of the National NPC1
Disease Database reports i) further characterization of plasma lipoprotein abnormalities in NPC1 disease, ii) associations between the lipid profiles, gene mutations, and biochemical phenotypes in NPC1 patients, iii) possible correlations between the lipid and/or physicians responsible for patients with NPC1 disease living in the United States.
The questionnaire did not specifically request information concerning who provided the initial diagnosis of NPC1 disease (primary care physician, pediatrician, neurologist, or other specialist). However, in all cases the parents/caregivers and/or patients were informed of the diagnosis for NPC1 disease after either genotype analysis, enhanced filipin staining and/or decreased cholesterol esterification using cultured fibroblasts derived from patients, consistent with the age at diagnosis reported in the questionnaire and the time of identification of the NPC1 gene.
NPC1 lipid profiles and gene mutations
Fasting lipid profiles, all of which were obtained from a certified clinical 
Analysis of NPC1 mutations, biochemical phenotype, and lipid profiles
The majority of known NPC1 mutations have been associated with specific biochemical phenotypes as defined by measuring the esterification of LDL-derived cholesterol in skin fibroblasts obtained from NPC1 patients (28, 30, 33, 39, 40) . To further analyze NPC1 mutations and biochemical phenotypes in relation to different components of the lipid profile, the biochemical phenotypes were assigned a severity score based on the reduction in cholesterol esterification by ACAT as previously described (30) . For example, a variant biochemical phenotype, represented by a mild mutation with a near normal biochemical phenotype, was given a score of one (1) . A moderate biochemical phenotype, represented by an intermediate mutation and biochemical phenotype, was given a score of two (2) . A classical biochemical phenotype, represented by a classical mutation that was more severe than the moderate mutation, but less severe than a severe mutation, was given a score of three (3) . A severe biochemical phenotype, represented by a severe mutation and biochemical phenotype, was given a score of four (4) . In cases where the biochemical phenotype was unknown, no score was assigned (unknown = U). In order to assign a biochemical phenotype score for the combination of two different NPC1 mutations, the following rules were applied: 1) One moderate mutation always conferred a moderate biochemical phenotype, 2) classical mutations known to be variable always depended upon the other mutation, and 3) one severe mutation always conferred a severe biochemical phenotype.
Statistical analysis
The clinical information, lipid profiles, and gene mutations were entered into a
Microsoft ACCESS database and analyzed by the Data Analysis Unit, University of Arizona Program Site of the Arizona University Center on Disabilities. Pearson correlation coefficients were computed to evaluate relationships among most of the variables in this report. However, Spearman's rank correlation coefficient was substituted whenever the biochemical phenotype score, which represents an ordinal scale variable, was used in an analysis. Significance was determined by P-values < 0.05. All statistics and significance tests were computed using SPSS version 14.0.
RESULTS

Lipid profiles of NPC1 patients
For the present study, a total of 136 questionnaires were mailed to NPC1 families living in the United States, with 88 of these questionnaires (65%) being returned. For the 88 questionnaires returned, the lipid profiles from 34 patients (39%) were made available. The patients in this sample were represented by an approximately equal number of males (N = 18) and females (N = 16), ranging in age between 1.5 and 45
years, and at different stages and severity of disease. For these patients, the average concentrations (± SE) of total cholesterol were 146 ± 5.6 mg/dl (3.78 ± 0.14 mmol/l),
and triglycerides 126 ± 8.7 mg/dl (1.42 ± 0.10 mmol/l). The lipid profiles were grouped by gender and age ≤14 or >14 to determine whether there were gender or age-specific differences among these patients ( Fig.1) . No significant differences were found among any of the lipid parameters when comparing male or female NPC1 patients based on age <14 or >14. However, several significant differences were found when comparing the NPC1 patient lipid levels with a control population represented by normal males and females between 5-9 and 25-29 years of age as reported in the Lipid Research Clinics Population Studies Data Book (38) ( Table 1) . Total cholesterol levels were found to be significantly lower in female children and adult men with NPC1 disease, but not in male children or adult females. LDL-C was significantly lower than controls in female children and adult males and females with NPC1 disease, but not male children. Triglycerides were found to be significantly higher in male and female children and adult women with NPC1 disease, but not adult males. HDL-C was found to be significantly lower in all male and female NPC1 patient groups when compared to controls, regardless of age, with HDL-C ranging from 56% to 78% lower than controls across the groups. In 
Association among components of the lipid profile, age, and average ability score of NPC1 patients
We next analyzed associations among individual components of the lipid profiles with each other, age, and average ability score using the 34 lipid profiles available in the database. Significant associations were found between total cholesterol and LDL-C (P < 0.0005), between total cholesterol and triglycerides (P = 0.001), and between LDL-C and triglycerides (P = 0.037) ( Table 2 ). In contrast, we did not find a significant correlation between plasma HDL-C and triglycerides in these NPC1 patients (P = 0.059), suggesting the low HDL-C in NPC1 disease is a consequence of factors other than triglyceride replacement of cholesterol on HDL particles. When components of the lipid profile, age, and average ability scores were analyzed for possible associations, the results indicated that the concentration of LDL-C was directly and significantly associated with the age of patients, but inversely related to the average ability score (Table 3) . HDL-C level was not found to correlate with average ability score. Although information was made available from only five patients, the results, however, indicated that the concentration of HDL-C was directly and significantly associated with the age at death.
Molecular and biochemical characterization of the NPC1 gene mutations
Of the 88 questionnaires returned, the specific NPC1 gene mutations from 52 patients (59%) were made available ( Table 4) . Thirty-one of the patients were male (60%), and 21 were female (40%). The patients ranged in age from 1.5 and 48. of the patients in this survey.
Gene mutations, biochemical phenotype, and lipid profile
Of the 88 questionnaires received, both NPC1 mutation and lipid profile information were provided for 19 patients (22%), which were then used for independent analysis ( Table 5 ). This sample consisted of 13 males and 6 females, ranging in age While the lipoprotein profiles of NPC disease patients have previously been reported to be normal (1), one study did report a reduction in plasma total cholesterol in a small group of male NPC subjects, but did not report the distribution of cholesterol among lipoprotein fractions (42) . Our previous study found a preponderance of low HDL-C in 81% of a group of 21 male and female NPC1 disease patients of ages ranging from age 3 to 42 (35) . In the current study, the most consistent lipoprotein abnormality in male and female NPC1 patients of varying ages was again low plasma HDL-C.
Plasma HDL-C in these individuals did not correlate significantly with plasma triglycerides, suggesting the reduction in HDL-C is not on the basis of replacement of cholesterol by triglyceride on HDL particles, or more rapid clearance of HDL particles from plasma, as is reported to occur with triglyceride-enriched HDL (43) . Consistent with this conclusion, Shamburek et al. also reported no increased rate of appearance in HDL-derived cholesterol in bile in NPC disease subjects (42) . We previously found impaired upregulation of ABCA1, the rate-limiting step in new HDL particle formation, in response to loading of human NPC1 disease fibroblasts with either LDL or nonlipoprotein cholesterol (35) , and that HDL formation by NPC1 disease cells could be Since identification of the NPC1 gene, several studies have reported specific disease-causing mutations among different populations and ethnic groups (27, 29, 30, 32, 39, 51, 52) . In the present study, the 52 patients that provided gene mutations ranged in age between 1.5 and 48.5 years of age, and were at different stages and severity of disease. Of the 101 total mutations reported, 52 were found to be different, while the remaining 49 were similar and shared among patients. As each patient would be expected to provide at least 2 mutations for a total of 104, three of the patients were only able to provide one mutation, thereby suggesting that three patients had mutations patients in the present study was the relatively common I1061T missense mutation, known to be a particularly frequent mutation among NPC1 patients of Western
European decent (33) . In contrast, other frequent mutations (P474L, G992W, and R518Q) commonly associated with NPC1 patients of Italian, Nova Scotian, or Japanese decent, respectively, were either represented once or absent from this sample of patients.
In summary, the current report of the National Niemann-Pick Type C1 Disease
Database found i) a significantly decreased concentration of plasma LDL cholesterol and increased plasma triglycerides in the majority of NPC1 disease patients, ii) a significantly decreased concentration of HDL cholesterol for all patient groups that was not associated with the concentration of plasma triglycerides, iii) a significant inverse association between the concentration of HDL cholesterol and biochemical phenotype, and HDL cholesterol and age of death, for NPC1 patients, and iv) five previously unreported disease-causing mutations in NPC1. These results indicate the presence of a unique NPC1-related dyslipidemia, characterized particularly by hypoalphalipoproteinemia that may serve as a valuable and convenient biomarker of the biochemical severity of the disease, in addition to monitoring the potential benefit of therapies used for the eventual treatment of NPC disease. (38) . Values in bold are in mg/dl; equivalent values in mmol/l are shown in italics. One-sample t-tests were performed using the mean values for both the gender and age of normal individuals and NPC1 patients to determine significant differences. The average ability score was computed by taking the mean of the four individual abilities as assessed on the questionnaire. These abilities included walking, movement, language, and swallowing. Each of the individual abilities were ranked from 1 to 4, or 1 to 5, with a score of "1" being normal and scores of "4" or "5" being the most severe level of disability. NS = Not significant. (30) . b The lumen (LM), transmembrane (TM), cytoplasmic (CP), and sterol sensing (SSD) protein domains are provided as previously indicated (30, 53) .
c The biochemical phenotypes of respective nucleotide and/or amino acid changes are based upon the degree of cholesterol esterification catalyzed by acyl-CoA:cholesterol acyltransferase (ACAT), and were provided for known nucleotide and/or amino acid changes as previously indicated (30) .
d Number of respective variations within the sample of NPC1 patients are provided, whereby polymorphisms (P) and novel (N) mutations are indicated. 
